Letrozole is a non-steroidal aromatase inhibitor that interacts reversibly with CYP19A1 through coordination of its triazole nitrogen with the enzyme's haem iron center. Steroidal aromatase inhibitors utilize a different structural framework and interact with the enzyme through distinct molecular mechanisms.

These differences make letrozole a valuable research tool for comparative investigations of aromatase inhibition, enzyme-ligand interactions, active-site binding characteristics, and CYP19A1 pharmacology.

Letrozole is a highly selective CYP19A1 inhibitor widely used to investigate aromatase-mediated catalytic processes, steroidogenic pathway regulation, enzyme kinetics, and substrate-enzyme interactions. Experimental studies employ letrozole to examine the role of aromatase within hormone biosynthesis networks, transcriptional regulation of steroidogenic pathways, and the molecular consequences of selective CYP19A1 inhibition.

Letrozole demonstrates high affinity for CYP19A1 and exhibits potent inhibition of aromatase activity in experimental systems. Its well-characterized interaction with the aromatase active site has established it as a reference compound for studies of enzyme inhibition, concentration-response relationships, inhibitor selectivity, and comparative aromatase pharmacology.

These characteristics make letrozole a valuable tool for mechanistic investigations of CYP19A1 function and regulation.